Scarica l'app Stockscreener
2.36
1.72%
0.04
Dopo l'orario di chiusura:
2.31
-0.05
-2.12%
Precedente Chiudi:
$2.32
Aprire:
$2.4612
Volume 24 ore:
33,866
Relative Volume:
1.94
Capitalizzazione di mercato:
$16.50M
Reddito:
-
Utile/perdita netta:
$-33.65M
Rapporto P/E:
-0.4739
EPS:
-4.98
Flusso di cassa netto:
$-20.83M
1 W Prestazione:
-7.25%
1M Prestazione:
-10.02%
6M Prestazione:
-0.42%
1 anno Prestazione:
-57.17%
Intervallo 1D:
$2.33
$2.4612
Intervallo di 1 settimana:
$2.30
$2.83
Portata 52W:
$2.26
$13.49
Minerva Neurosciences Inc Stock (NERV) Company Profile
Nome
Minerva Neurosciences Inc
Settore
Industria
Telefono
617-600-7373
Indirizzo
1601 TRAPELO ROAD, WALTHAM, MA
Minerva Neurosciences Inc Stock (NERV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-06-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-14 | Iniziato | BTIG Research | Buy |
| 2019-10-02 | Reiterato | Chardan Capital Markets | Buy |
| 2019-09-25 | Iniziato | Chardan Capital Markets | Buy |
| 2019-09-18 | Iniziato | William Blair | Outperform |
| 2019-05-31 | Iniziato | H.C. Wainwright | Buy |
| 2017-09-01 | Iniziato | Citigroup | Buy |
| 2017-03-06 | Ripresa | Jefferies | Buy |
| 2016-05-12 | Ripresa | Jefferies | Buy |
Mostra tutto
Minerva Neurosciences Inc Borsa (NERV) Ultime notizie
Minerva Neurosciences: Q3 Earnings Snapshot - San Francisco Chronicle
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates - GlobeNewswire
Major Depressive Disorder Market Expected to Experience Major Growth by 2034, According to DelveInsight | Takeda, Otsuka Pharma, AbbVie, SAGE Therapeutics, Forest Laboratories, Axsome Therapeutics - The Globe and Mail
Cognitive Impairment Disorders Treatment A Game Changer for Global Finance Forecast-Eli Lilly and Company, AstraZeneca, – IndiaPolitics.com - IndiaPolitics.com
Japan Receptor Tyrosine Protein Kinase ERBB 4 Industry Size, Share, Price, Trends, Forecast (2024-2034) - IndiaPolitics.com
Minerva Neurosciences (NASDAQ:NERV) Share Price Passes Below 200-Day Moving Average – What’s Next? - Defense World
Schizophrenia Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Reviva Pharma, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharma, Boehringer Ingelheim, Sunovion - Barchart
Neurological diseases index falls; Sarepta and Intra-Cellular report gains - BioWorld Online
Inari Medical director sells $1.83M in common stock - TipRanks
Intuitive Machines Shares Soar on NASA Pact for Near-Space Grid - Bloomberg
Intuitive Machines Stock Soars on New NASA Contract. This Is Big. - Barron's
Intuitive Machines Stock Is Soaring Wednesday: What's Going On? - Benzinga
Why Intuitive Machines Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket - Benzinga
After-hours movers: Intuitive Machines, Casella Waste Systems, Galmed Pharma, Edgewise Therapeutics - Investing.com Australia
Minerva Neurosciences (NASDAQ:NERV) Receives New Coverage from Analysts at StockNews.com - Defense World
Rathbones Group PLC Increases Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) - MarketBeat
INmune Bio stock dips on $13M securities offering - MSN
Minerva Neurosciences (NASDAQ:NERV) versus AC Immune (NASDAQ:ACIU) Head-To-Head Survey - Defense World
StockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV) - Defense World
Rubertis Francesco De Net Worth (2024) - GuruFocus.com
Minerva Neurosciences (NASDAQ:NERV) Now Covered by Analysts at StockNews.com - Defense World
Research Analysts Issue Forecasts for Minerva Neurosciences, Inc.’s Q3 2024 Earnings (NASDAQ:NERV) - Defense World
Minerva Neurosciences (NASDAQ:NERV) Price Target Cut to $5.00 - Defense World
HC Wainwright Weighs in on Minerva Neurosciences, Inc.’s Q4 2024 Earnings (NASDAQ:NERV) - Defense World
Minerva Neurosciences: Q2 Earnings Snapshot - San Antonio Express-News
Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates - GlobeNewswire
Minerva Neurosciences (NASDAQ:NERV) Now Covered by StockNews.com - Defense World
Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com - Defense World
Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated at StockNews.com - Defense World
Minerva Neurosciences (NASDAQ:NERV) Share Price Crosses Below 200 Day Moving Average of $4.42 - Defense World
StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV) - Defense World
Cognitive Behavioral Therapy for Insomnia Market Insights, Industry Outlook, Growing Trends with Top Key Players – MINERVA NEUROSCIENCES INC, CURRAX PHARMACEUTICALS LLC, Pfizer Inc., Sanofi, zydus cadila – TIMC - TIMC
Minerva Neurosciences (NASDAQ:NERV) Stock Price Passes Below 200-Day Moving Average of $4.54 - Defense World
Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates - Zacks Investment Research
Are Options Traders Betting on a Big Move in Minerva Neurosciences (NERV) Stock? - Yahoo Lifestyle UK
Design, Sarepta, Wave rise amid overall neurological index decline - BioWorld Online
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates - Quantisnow
Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market - Quantisnow
Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates - Quantisnow
Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023 - Quantisnow
Minerva Neurosciences to Present at JMP Securities Life Sciences Conference - Quantisnow
Minerva Neurosciences and Royalty Pharma Announce Sale of Seltorexant Royalty for up to $155 Million - Quantisnow
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates - Quantisnow
Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021 - Quantisnow
Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8 - Quantisnow
Minerva Neurosciences to Report First Quarter 2021 Financial Results and Business Updates on May 12, 2021 - Quantisnow
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates - Quantisnow
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of ... - Quantisnow
Minerva Neurosciences Announces Promotion of Geoff Race to President - Quantisnow
Implied Volatility Surging for Minerva Neurosciences (NERV) Stock Options - Yahoo New Zealand News
Minerva Neurosciences (NASDAQ:NERV) Share Price Crosses Above 50-Day Moving Average of $2.74 - Defense World
Minerva Neurosciences Inc Azioni (NERV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):